/EINPresswire.com/ SUNNYVALE, CA – January 20, 2012 – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, was interviewed at the 2012 Biotech Showcase in San Francisco last week. The interview can be accessed via the following link: http://stocknewsnow.com/?p=2825.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”). For further information please visit www.amarantus.com.
MEDIA CONTACT:
Lou Levenstein
727.489.9939
info@seraphimstrategies.com
